SCM LifeScience Co

SCM LifeScience Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is -239.38 M KRW. In the previous year, Stock-Based Compensation (SBC) was 41.96 M KRW — a change of -670.53% (lower).

Stock-Based Compensation

-239.38 MKRW

YoY

-670.53%

Last updated:

Stock-Based Compensation (SBC) of SCM LifeScience Co is 2025 -239.38 M KRW. Stock-Based Compensation (SBC) of SCM LifeScience Co was 2024 41.96 M KRW. It decreases by -670.53% lower compared to the previous year.

The SCM LifeScience Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
1.78 B KRW
Jan 1, 2020
4.30 B KRW
Jan 1, 2021
-1.97 B KRW
Jan 1, 2022
664.68 M KRW
Jan 1, 2023
614.04 M KRW
Jan 1, 2024
41.96 M KRW
Jan 1, 2025
-239.38 M KRW
The SCM LifeScience Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
-239.38 MKRW-670.53%
41.96 MKRW-93.17%
614.04 MKRW-7.62%
664.68 MKRW-133.68%
-1.97 BKRW-145.93%
4.30 BKRW+141.55%
1.78 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Stock-Based Compensation (SBC) of SCM LifeScience Co is -239.38 M KRW in 2025.

Stock-Based Compensation (SBC) of SCM LifeScience Co changed from 41.96 M KRW to -239.38 M KRW, representing a -670.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s SCM LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co